• AAPL 166.82
  • TSLA 144.61
  • AMZN 179.515
  • MSFT 407.055
  • INTC 34.27
  • EURUSD 1.0704
Overview Fundamentals API Earnings EOD API Sample Code Pricing
Register now
Free trial

No credit cards required

Get free API key
  1. Supported exchanges /
  2. PINK /
  3. NONOF.PINK

Novo Nordisk A/S (NONOF PINK) stock market data APIs

$120.01 -6.25(-5%) as of April 22, 2024

Novo Nordisk A/S Financial Data Overview

126.262
120.01
-
127
117.9
74.3461-140.32
557 833 M
47.4669
3 387 M
232 261 M
0.7073
0.0147
0.195
Our easy-to-use no-coding solutions help you get the data effortlessly:
Excel Financial Add-In Google Sheets Financial Add-In Python
APIs SDK Windows Downloader

No long-term obligations. The minimum period is one month only. No wait. You get an API key with instructions in a few seconds right after subscription.

General: {
Code: 'NONOF',
Type: 'Common Stock',
Name: 'Novo Nordisk A/S',
Exchange: 'PINK',
CurrencyCode: 'USD',
CurrencyName: 'US Dollar',
CurrencySymbol: '$',
CountryName: 'USA',
CountryISO: 'US',
ISIN: NULL,
CUSIP: NULL,
CIK: '353278',
EmployerIdNumber: NULL,
FiscalYearEnd: 'December',
IPODate: NULL,
InternationalDomestic: NULL,
Sector: 'Healthcare',
Industry: 'Biotechnology',
HomeCategory: NULL,
IsDelisted: false,
}

Novo Nordisk A/S Fundamental Data is available in our Financial Data APIs

  • Net Revenue 232 261 M
  • EBITDA 109 813 M
  • Earnings Per Share 2.66
  • Income Statements
  • Balance Sheets
  • Cash flows
Fundamental data package from $59.99 See full price
Get sample
of Fundamental API Data

Get Novo Nordisk A/S Earnings via APIs

  • Latest Release 2023-12-31
  • EPS/Forecast NaN

Get Novo Nordisk A/S End-of-day Data via APIs

  • End of Day, Intraday and Live APIs
  • Splits
  • Dividends

Get Novo Nordisk A/S latest news via APIs

Novo Nordisk A/S - share repurchase programme

Novo Nordisk A/S Bagsværd, Denmark, 22 April 2024 – On 6 February 2024, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European P...

India's Biocon developing its own version of Wegovy, clinical trial likely next year

By Rishika Sadam HYDERABAD (Reuters) - Indian drugmaker Biocon, looking to grab a piece of the exploding weight-loss drug market as early as possible, is developing its own version of Novo Nordisk's ...
Do you have any questions?
support@eodhistoricaldata.com